Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Fulvestrant|DRUG: Everolimus|DRUG: Placebo
Sponsor: PrECOG, LLC.
Collaborators: Novartis